cytarabine has been researched along with Left Ventricular Dysfunction in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB | 1 |
| Ala-Kopsala, M; Hartikainen, J; Husso-Saastamoinen, M; Jantunen, E; Kuittinen, T; Nousiainen, T; Sipola, P; Vuolteenaho, O | 1 |
| Ala-Kopsala, M; Hartikainen, J; Jantunen, E; Kuittinen, T; Mussalo, H; Nousiainen, T; Vanninen, E; Vuolteenaho, O | 1 |
| Ahmed, T; Baskind, P; Darzynkiewicz, Z; Feldman, EJ; Goff, H; Pozzuoli, M; Santos, S; Seiter, K; Traganos, F | 1 |
2 trial(s) available for cytarabine and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Conjunctivitis; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Remission Induction; Risk; Stomatitis; Stroke Volume; Survival Analysis; Survival Rate; Treatment Outcome; Tretinoin; Ventricular Dysfunction, Left | 2000 |
2 other study(ies) available for cytarabine and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular System; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Heart; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptides; Peptides; Prospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Ventricular Dysfunction, Left; Ventricular Function, Left | 2005 |
Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gated Blood-Pool Imaging; Heart; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Postoperative Period; Prospective Studies; Protein Precursors; Sensitivity and Specificity; Stroke Volume; Systole; Transplantation, Autologous; Ventricular Dysfunction, Left | 2006 |